Nektar Therapeutics stock falls 9.6 percent as patent case weighs

Published on 09/23/2026 at 02:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Nektar Therapeutics stock fell to USD 60.434 on September 22, 2026, after a jury deliberated in the Rezpeg patent dispute. Quarterly EPS beat by USD 0.74.

NKTR, US6354171056, Illustration mit AI erstellt.

Nektar Therapeutics (ISIN US6354171056) fell 9.6 percent to USD 60.434 on Nasdaq on September 22, 2026, as a jury deliberated in the patent dispute concerning Rezpeg. The session low was USD 61.74, while the prior close was USD 66.84.

Patent dispute drives the move

As Seeking Alpha reported on September 22, 2026, NKTR quickly sank 11 percent while the jury considered the dispute with Eli Lilly over Rezpeg. The report said the jury had been deliberating since Friday and had asked about outcomes involving low or no damages.

The legal uncertainty matters because Rezpeg is one of Nektar's key investigational therapies. The company is developing immune-modulating medicines for autoimmune and inflammatory diseases, making the court outcome a direct risk to the valuation assigned to its pipeline.

Quarterly loss beats estimates

Nektar's latest reported quarter, released on August 13, 2026, showed a loss of USD 1.23 per share. According to MarketBeat on September 22, 2026, that result was USD 0.74 better than the consensus estimate of a USD 1.97 loss.

Revenue for the same quarter was USD 10.13 million, below the USD 10.43 million analyst expectation by USD 0.30 million, according to MarketBeat. The quarter therefore combined a narrower-than-expected loss with a revenue miss, leaving clinical and legal developments central to the stock story.

Stock remains below yearly high

MarketBeat data on September 22, 2026, put Nektar's market capitalization at USD 2.10 billion and mid-day volume at 1,153,889 shares, compared with an average session volume of 1,008,141 shares. The one-year range was USD 33.40 to USD 109.00, placing the latest price USD 48.566 below the high and USD 27.034 above the low.

BTIG Research reiterated a Buy rating and set a USD 178.00 price objective in a research note dated September 16, 2026, according to MarketBeat. That target is USD 117.566 above the September 22 price, but the gap also highlights how strongly the investment case depends on clinical progress and resolution of the patent litigation.

Nasdaq price closes at USD 60.434

Nektar Therapeutics closed at USD 60.434 on Nasdaq on September 22, 2026, down 9.6 percent from the USD 66.84 prior close. Market capitalization was USD 2.10 billion as of September 22, 2026.